We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Factors to Watch Before Post Holdings' (POST) Q2 Earnings
Read MoreHide Full Article
Post Holdings, Inc. (POST - Free Report) is scheduled to release second-quarter fiscal 2020 results on May 7. The company delivered a negative earnings surprise of 33.3% in the last reported quarter.
The Zacks Consensus Estimate for second-quarter earnings has gone up by 4.6% in the past seven days to 91 cents per share. However, this suggests a decrease of 28.9% from the figure reported in the year-ago quarter. Meanwhile, the consensus mark for revenues stands at $1,413 million, indicating a rise of 1.8% from the year-ago period’s reported figure.
The company has been benefiting from contributions from its buyouts and other efforts to expand the customer base. In this regard, the company’s acquisition of Weetabix Limited (July 2017) has been yielding results. Further, Post Holdings’ acquisition of Bob Evans (Jan 2018) has strengthened its position in the foodservice and refrigerated retail channels. In fact, the company’s foodservice segment has been performing well for the past few quarters and gaining from solid performance in Bob Evans side dishes.
However, the company has been witnessing increasing SG&A expenses, which is concerning. Also, the company recently informed that on Feb 27 a fire broke out at its Michael Foods farm operation in Bloomfield, NE.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Post Holdings this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat.
Hain Celestial (HAIN - Free Report) has an Earnings ESP of +9.24% and a Zacks Rank #1.
Smucker (SJM - Free Report) has an Earnings ESP of +1.65% and a Zacks Rank #1.
Flowers Foods (FLO - Free Report) has an Earnings ESP of +7.77% and a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Factors to Watch Before Post Holdings' (POST) Q2 Earnings
Post Holdings, Inc. (POST - Free Report) is scheduled to release second-quarter fiscal 2020 results on May 7. The company delivered a negative earnings surprise of 33.3% in the last reported quarter.
The Zacks Consensus Estimate for second-quarter earnings has gone up by 4.6% in the past seven days to 91 cents per share. However, this suggests a decrease of 28.9% from the figure reported in the year-ago quarter. Meanwhile, the consensus mark for revenues stands at $1,413 million, indicating a rise of 1.8% from the year-ago period’s reported figure.
Post Holdings, Inc. Price and EPS Surprise
Post Holdings, Inc. price-eps-surprise | Post Holdings, Inc. Quote
Key Factors to Note
The company has been benefiting from contributions from its buyouts and other efforts to expand the customer base. In this regard, the company’s acquisition of Weetabix Limited (July 2017) has been yielding results. Further, Post Holdings’ acquisition of Bob Evans (Jan 2018) has strengthened its position in the foodservice and refrigerated retail channels. In fact, the company’s foodservice segment has been performing well for the past few quarters and gaining from solid performance in Bob Evans side dishes.
However, the company has been witnessing increasing SG&A expenses, which is concerning. Also, the company recently informed that on Feb 27 a fire broke out at its Michael Foods farm operation in Bloomfield, NE.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Post Holdings this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Post Holdings carries a Zacks Rank #3 and an Earnings ESP of -15.15. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks With Favorable Combinations
Here are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat.
Hain Celestial (HAIN - Free Report) has an Earnings ESP of +9.24% and a Zacks Rank #1.
Smucker (SJM - Free Report) has an Earnings ESP of +1.65% and a Zacks Rank #1.
Flowers Foods (FLO - Free Report) has an Earnings ESP of +7.77% and a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>